Newly developed humanized anti‐ CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1 ‐ CKAP4 signaling
Cancer Science · 2024
DOI: 10.1111/cas.16278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Ryota Sada und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Biochemistry, Graduate School of Medicine, Osaka University, Suita, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Intercellular Signaling Peptides and Proteins, Signal Transduction, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Cytoskeleton‐associated protein 4 (CKAP4) is a cell surface receptor for Dickkopf 1 (DKK1), a secreted protein. The DKK1–CKAP4 pathway is activated in various malignant tumors, including pancreatic, lung, esophageal, and liver cancers, to promote tumor growth. Thus, CKAP4 has been expected to represent a novel molecular target of cancer therapy. Recombinant mouse anti‐CKAP4 antibodies were generated based on an original mouse antibody (3F11‐2B10) and inhibited DKK1–CKAP4 signaling and xenograft tumor formation induced by pancreatic cancer cells, which was comparable with 3F11‐2B10. From the 3F11‐2B10 nucleotide sequence, humanized anti‐CKAP4 antibody (Hv1Lt1) was subsequently developed. The binding affinity of Hv1Lt1 for CKAP4 was superior to that of 3F11‐2B10. Hv1Lt1 inhibited DKK1 binding to CKAP4, AKT activity, and sphere formation of pancreatic cancer cells, which was comparable with 3F11‐2B10. Hv1Lt1 also suppressed xenograft tumor formation induced by human pancreatic cancer cells and tumor growth in murine cancer models, in which murine pancreatic cancer organoids were orthotopically transplanted into the pancreas. In resected tumor samples from mice treated with Hv1Lt1, anti‐tumor immune reactions were modulated and cytotoxic T cells were highly infiltrated in the tumor microenvironment. Additionally, combination of Hv1Lt1 and other chemotherapy drugs exhibited stronger effects compared with monotherapy. These results suggest that Hv1Lt1 represents a promising anti‐cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Biochemistry, Graduate School of Medicine, Osaka University, Suita, Japan.
- Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Japan.
- Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Japan.
- Department of Health Care Sciences, Jikei University of Health Care Sciences, Osaka, Japan.
ORCID-Profile: Ryota Sada, Shinji Matsumoto
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Sada, R., Yamamoto, H., Matsumoto, S., Harada, A., & Kikuchi, A. (2024). Newly developed humanized anti‐ CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1 ‐ CKAP4 signaling. Cancer Science. https://doi.org/10.1111/cas.16278
Vancouver
Sada R, Yamamoto H, Matsumoto S, Harada A, Kikuchi A. Newly developed humanized anti‐ CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1 ‐ CKAP4 signaling. Cancer Science. 2024. doi:10.1111/cas.16278
BibTeX
@article{Sada2024,
author = {Sada, Ryota and Yamamoto, Hideki and Matsumoto, Shinji and Harada, Akikazu and Kikuchi, Akira},
title = {Newly developed humanized anti‐ CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1 ‐ CKAP4 signaling},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16278}
}
EUVIMED